Marker Therapeutics (MRKR) Non-Current Assets (2010 - 2023)
Marker Therapeutics (MRKR) posted quarterly Non-Current Assets of $17.0 million for Q1 2023, down 28.87% year-over-year from $23.9 million in Q1 2022, and down 4.35% quarter-over-quarter from $17.8 million in Q4 2022.
Marker Therapeutics (MRKR) Non-Current Assets (2010 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Non-Current Assets for 10 consecutive years, with $17.0 million the latest figure, recorded in Q1 2023.
- In Q1 2023, Non-Current Assets fell 28.87% year-over-year to $17.0 million; the TTM figure through Mar 2023 stood at $17.0 million (down 28.87% YoY), while the FY2022 annual figure was $17.8 million, down 19.64% from the prior year.
- Non-Current Assets slipped to $17.0 million in Q1 2023 per MRKR's latest filing, from $17.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $23.9 million in Q1 2022 and bottomed at $872702.0 in Q4 2019.
- Historically, Non-Current Assets has averaged $14.3 million across 5 years, with a median of $18.2 million in 2020.
- Annual changes were most pronounced in 2020 — Non-Current Assets surged 2329.69% — and 2023, when it decreased 28.87%.
- Marker Therapeutics' Non-Current Assets stood at $872702.0 in 2019, then soared by 2329.69% to $21.2 million in 2020, then gained by 4.48% to $22.2 million in 2021, then decreased by 19.64% to $17.8 million in 2022, then dropped by 4.35% to $17.0 million in 2023.
- Business Quant data shows MRKR's Non-Current Assets at $17.0 million in Q1 2023, $17.8 million in Q4 2022, and $18.7 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 17.03 Mn |
| Dec 31, 2022 | 17.80 Mn |
| Sep 30, 2022 | 18.69 Mn |
| Jun 30, 2022 | 23.04 Mn |
| Mar 31, 2022 | 23.94 Mn |
| Dec 31, 2021 | 22.15 Mn |
| Sep 30, 2021 | 20.53 Mn |
| Jun 30, 2021 | 20.45 Mn |
| Mar 31, 2021 | 20.89 Mn |
| Dec 31, 2020 | 21.20 Mn |
| Sep 30, 2020 | 18.25 Mn |
| Jun 30, 2020 | 13.76 Mn |
| Mar 31, 2020 | 889,897.00 |
| Dec 31, 2019 | 872,702.00 |
| Sep 30, 2019 | 940,595.00 |
| Jun 30, 2019 | 960,694.00 |
| Mar 31, 2019 | 952,702.00 |
| Dec 31, 2018 | 147,668.00 |
| Mar 31, 2013 | 33,950.00 |
| Sep 30, 2012 | 20,768.00 |